Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAsian Institute of Gastroenterology, India

About this trial

Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Duration: 12 months Sample Size: 100 UC patients (Colonoscopy + IBUS), 100 CD patients (CT/MRI enterography + IBUS), Total: 200 Patients

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

200 Participants
are grouped into 2 trial groups
Group A: Ulcerative colitis
Group B: Crohns disease

Trial outcomes

Primary outcomes

1

The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed

The waste generated will be stratified according to the methods of disposal as Direct landfill, Incineration, and landfill or Recyclable waste. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed. The unit of emissions will remain same kgCO2e and the total emissions will then be calculated.

Time frame
12 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.